Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 14/20 | 0.61 |
| ▸ | KEAP1 | Q14145 | 6/20 | 0.53 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17612866 | 1.00 | NOTUM (0.61) | NOTUMKEAP1NFE2L2 | |
| SCHEMBL24811432 | 1.00 | NOTUM (0.61) | NOTUMKEAP1NFE2L2 | |
| SCHEMBL17612867 | 0.81 | LGMN (0.57) | — | |
| SCHEMBL17612877 | 0.80 | KEAP1 (0.67) | NOTUMKEAP1NFE2L2 | |
| SCHEMBL17599443 | 0.79 | CTSB (0.59) | NOTUMKEAP1NFE2L2 | |
| SCHEMBL17599487 | 0.79 | CTSB (0.59) | NOTUMKEAP1NFE2L2 | |
| SCHEMBL1749472 | 0.78 | RPS6KB1 (0.48) | NOTUMKEAP1NFE2L2 | |
| SCHEMBL1749473 | 0.78 | OPRM1 (0.40) | NOTUMKEAP1NFE2L2 | |
| SCHEMBL4769598 | 0.75 | S1PR5 (0.53) | NOTUM | |
| SCHEMBL4662970 | 0.75 | S1PR5 (0.53) | NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023122298-A1 | PROTEIN STABILIZING COMPOUNDS CONTAINING USP28 AND/OR USP25 TARGETING LIGANDS | Stablix, Inc. (US) | 2023-06-29 | — | — | WO | disclosed |
| EP-2997966-A1 | Naphthyl Sulfonamide Pyrrolidine Derivatives as KEAP-1 Modulators for the Treatment of Diabetes, Obesity, Dyslipidemia and Related Disorders | SANOFI (FR) | 2016-03-23 | — | — | EP | disclosed |
| EP-2997966-A1 | Naphthyl Sulfonamide Pyrrolidine Derivatives as KEAP-1 Modulators for the Treatment of Diabetes, Obesity, Dyslipidemia and Related Disorders | SANOFI (FR) | 2016-03-23 | — | — | EP | disclosed |